CLINICAL USE

Hyperprolactinaemia

DOSE IN NORMAL RENAL FUNCTION

75–150 micrograms daily

PHARMACOKINETICS

  • Molecular weight                           :432 (as hydrochloride)
  • %Protein binding                           :90
  • %Excreted unchanged in urine     : Very little, most is excreted as metabolites in faeces and urine
  • Volume of distribution (L/kg)       :100 litres
  • half-life – normal/ESRD (hrs)      :17

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Use with caution Start with low dose and titrate according to response
  • 10 to 20     : Use with caution Start with low dose and titrate according to response
  • <10           : Use with caution Start with low dose and titrate according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min
  • HD                     :Unknown dialysability. Dose as in GFR <10 mL/min
  • HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Manufacturer advises to avoid use in renal impairment due to lack of dataRenally excreted metabolites (glucuronide and sulphate) are inactive.

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia